Yicheng Xiong

Dr. Yicheng Xiong


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2022 in Biomaterials
Verified
Journal Article
Closed access
YHYan Huang
Yan Huang
YXYang Xu
Yang Xu
JZJiachen Zhu
Jiachen Zhu
JWJian Wan
Jian Wan
YXYicheng Xiong
Yicheng Xiong
YYYumin Yang
Yumin Yang

14 November 2023 in Cellular Signalling
Verified
Journal Article
Closed access
YWYao Wang
Yao Wang
HDHaoxiang Ding
Haoxiang Ding
CGChengfeng Guo
Chengfeng Guo
QBQian Bao
Qian Bao
DLDongqian Li
Dongqian Li
YXYicheng Xiong
Yicheng Xiong

1 August 2025 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
CLChi Liang
Chi Liang
XJXiang Ji
Xiang Ji
SLShan Liu
Shan Liu
LXLiancheng Xu
Liancheng Xu
YXYicheng Xiong
Yicheng Xiong
GCGuanyi Cao
Guanyi Cao
Background: Hepatocellular carcinoma (HCC) is one of the most common solid tumors, resulting in poor survival and high mortality worldwide. MicroRNAs (miRNAs) contained in serum exosomes are being increasing used as targets for disease diagnosis and treatment. However, the role and the diagnostic potential of exosome-transported miRNAs in HCC remain largely underexplored. Therefore, this study aims to identify differentially expressed exosomal miRNAs in the serum of HCC patients and healthy individuals, clarify the biological function of the key miRNAs in HCC progression, and explore its potential as a diagnostic and therapeutic biomarker for HCC. Methods: In this study, the serum-derived exosomes of patients with HCC and healthy individuals were characterized via transmission electron microscopy (TEM), Western blot assay, and nanoparticle tracking analysis (NTA). The serum-derived exosomes were labeled with PKH-67, and the transport to recipient HCC cells was observed with confocal microscopy. Differentially expressed miRNAs (DEmiRs) encapsulated in serum-derived exosomes were screened via miRNA sequencing, the expression of which was verified through quantitative real-time polymerase chain reaction (qRT-PCR). The association between miR-675-3p and clinicopathological features was investigated via the chi-squared test. The gain and loss of function of miR-675-3p in HCC cells were examined through transfection with mimics and inhibitor. Cell Counting Kit-8 (CCK8), colony formation, 5-ethynyl-2’-deoxyuridine (EdU) staining, and Transwell assays were conducted to test the biological effects of overexpressed and inhibited miR-675-3p on HCC cells in vitro. Tumor xenograft models and immunohistochemistry (IHC) were performed to assess the malignant progression of HCC cells with downregulated miR-675-3p in vivo. Results: Uptake of exosomes from patients with HCC promoted the malignant phenotype of recipient cells. miRNA-675-3p within exosomes was confirmed to be upregulated in the serum of patients with HCC as compared with that of healthy donors. The chi-squared test results showed that miRNA-675-3p was associated with poor survival. Overexpression of miRNA-675-3p promoted the proliferation, invasion, and colony formation of HCC cells in vitro, while downregulation of miRNA-675-3p had the opposite biological effects on HCC cells and inhibited tumor growth and malignant progression in vivo. Furthermore, bioinformatics analysis indicated that miRNA-675-3p was involved in certain cellular processes, especially in lipid metabolism and regulation of several signaling pathways such as PI3K/AKT pathways and PPAR pathways. Conclusions: miRNA-675-3p was upregulated in the serum of patients with HCC and exerted an oncogenic role in HCC cells via the targeting of downstream genes. These findings may constitute novel insights into the development of HCC, with miRNA-675-3p potentially serving as a biomarker for the diagnosis and treatment of patients with HCC.

1 February 2026 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
CGChengfeng Guo
Chengfeng Guo
PSPingping Sun
Pingping Sun
KGKai Gao
Kai Gao
JAJiawei An
Jiawei An
HXHuien Xie
Huien Xie
YWYao Wang
Yao Wang
Background: Hepatocellular carcinoma (HCC) exhibits notable characteristics, encompassing frequent recurrence, weak immunotherapeutic outcomes and unfavorable prognosis. BTF3L4 has been identified as a critical factor in the progression of various malignancies. However, its specific role in HCC remains to be elucidated. This investigation sought to examine BTF3L4 levels in HCC and BTF3L4’s connection with clinical prognosis and immune infiltration. Methods: We performed an extensive multi-omics evaluation in the course of our research. Bioinformatics tools were utilized to assess BTF3L4 messenger RNA (mRNA) expression in HCC. Multiplex immunohistochemistry (mIHC) was utilized to examine BTF3L4 protein expression and to explore its correlation with tumor-infiltrating immune cells (TIICs). Cox regression analysis and Kaplan-Meier survival curves were applied to determine BTF3L4’s impact on patient outcomes. Results: Our analysis revealed markedly elevated levels of both BTF3L4 mRNA and protein in HCC tissues. BTF3L4 protein abundance emerged as an independent predictor of reduced survival in patients with HCC. Furthermore, elevated BTF3L4 protein expression was positively associated with cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) expression and markedly negatively correlated with CD4+ T cells and CD66b+ neutrophils in HCC tissues. Conclusions: This evidence indicates that BTF3L4 functions as a predictive indicator and is a potential candidate for HCC immunotherapy.

1 January 2024 in Genetics Research
Verified
Journal Article
Open access
DLDongqian Li
Dongqian Li
QBQian Bao
Qian Bao
SRShiqi Ren
Shiqi Ren
HDHaoxiang Ding
Haoxiang Ding
CGChengfeng Guo
Chengfeng Guo
YXYicheng Xiong
Yicheng Xiong
Background. Hepatocellular carcinoma (HCC), ranking as the second‐leading cause of global mortality among malignancies, poses a substantial burden on public health worldwide. Anoikis, a type of programmed cell death, serves as a barrier against the dissemination of cancer cells to distant organs, thereby constraining the progression of cancer. Nevertheless, the mechanism of genes related to anoikis in HCC is yet to be elucidated. Methods. This paper’s data (TCGA‐HCC) were retrieved from the database of the Cancer Genome Atlas (TCGA). Differential gene expression with prognostic implications for anoikis was identified by performing both the univariate Cox and differential expression analyses. Through unsupervised cluster analysis, we clustered the samples according to these DEGs. By employing the least absolute shrinkage and selection operator Cox regression analysis (CRA), a clinical predictive gene signature was generated from the DEGs. The Cell‐Type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT) algorithm was used to determine the proportions of immune cell types. The external validation data (GSE76427) were procured from Gene Expression Omnibus (GEO) to verify the performance of the clinical prognosis gene signature. Western blotting and immunohistochemistry (IHC) analysis confirmed the expression of risk genes. Results. In total, 23 prognostic DEGs were identified. Based on these 23 DEGs, the samples were categorized into four distinct subgroups (clusters 1, 2, 3, and 4). In addition, a clinical predictive gene signature was constructed utilizing ETV4, PBK, and SLC2A1. The gene signature efficiently distinguished individuals into two risk groups, specifically low and high, demonstrating markedly higher survival rates in the former group. Significant correlations were observed between the expression of these risk genes and a variety of immune cells. Moreover, the outcomes from the validation cohort analysis aligned consistently with those obtained from the training cohort analysis. The results of Western blotting and IHC showed that ETV4, PBK, and SLC2A1 were upregulated in HCC samples. Conclusion. The outcomes of this paper underscore the effectiveness of the clinical prognostic gene signature, established utilizing anoikis‐related genes, in accurately stratifying patients. This signature holds promise in advancing the development of personalized therapy for HCC.

6 March 2026 in Medicine
Verified
Journal Article
Open access
JAJiawei An
Jiawei An
MZMingyan Zhu
Mingyan Zhu
YFYangsuolang Mmed Fu
Yangsuolang Mmed Fu
KGKai Mmed Gao
Kai Mmed Gao
HXHuien Mmed Xie
Huien Mmed Xie
YXYicheng Xiong
Yicheng Xiong
While some observational research has pointed to a connection between inflammatory bowel disease and increased cirrhosis risk, it has been difficult to determine if this is a genuine cause-and-effect relationship. The challenge lies in separating actual causation from confounding factors that might influence both conditions. In this study, we turned to Mendelian randomization (MR) – a method that uses genetic variations as natural experiments – to investigate whether inflammatory bowel disease (IBD) truly causes cirrhosis. We performed a two-sample MR analysis. Genetic instruments for IBD were obtained from the IBD Genetics Consortium. Cirrhosis outcome data were sourced from both the FinnGen consortium and the UK Biobank, with summary statistics combined via fixed-effects meta-analysis. Methods included inverse-variance weighted, MR-Egger, weighted median, and sensitivity analyses (including Cochran Q test, MR-Egger intercept test, and leave-one-out analysis). The evidence from our MR analysis does not support a causal effect of IBD on cirrhosis risk. Our main analysis using inverse-variance weighted showed an odds ratio of 1.02 (95% confidence interval = 0.97–1.07, P = .42), indicating no significant association. Other methods told the same story, and our sensitivity analyses revealed no concerning heterogeneity or pleiotropy that might undermine these results. Put simply, our findings suggest that IBD does not directly cause cirrhosis. The associations seen in previous observational studies were likely driven by other factors that affect both conditions, rather than a direct biological pathway from IBD to liver damage.